Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

Karilyn Gower, Press Officer
w. (202) 588-7779

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Nicholas Florko, Communications Officer, Global Trade Watch
w. (202) 454-5108

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


Nov. 6, 2012  

FDA Rejects Petition to Ban Aricept 23: Did Drug Companies, FDA Collude in Approving Dangerous Alzheimer’s Drug?

Statement of Dr. Sidney Wolfe, Director, Public Citizen’s Health Research Group

Allowing drug manufacture Eisai to exploit and harm vulnerable patients with Alzheimer’s disease is unconscionable. With close to $700 million in drug industry money a year directly funding the Food and Drug Administration’s (FDA) drug review process, the question is whether the FDA, in this instance, was protecting the public health or, in effect, colluding with the drug industry when it denied a petition to ban Aricept 23, deciding to leave the dangerous drug on the market.

Eisai and Pfizer, peddlers of the biggest-selling Alzheimer’s drug of all time — with more than $2.4 billion U.S. sales in 2010 — were facing a threat to that revenue stream when the patent was set to expire on the lower-dose version of the drug. A study presented to the FDA in 2009 failed to show that Aricept 23 was more effective than the lower-dose drug in improving overall patient function and while showing it to be only minimally more effective in improving cognition.

Furthermore, the high dose was predictably associated with a much higher incidence of vomiting, which, in patients with Alzheimer’s disease, “can lead to pneumonia, massive gastrointestinal bleeding, esophageal rupture or death,” according to the FDA.

For this reason, the primary medical reviewer and the statistician at the FDA recommended that the agency deny the company’s application to market the higher-dose version of the drug.

That recommendation was rejected by the director of the FDA’s Division of Neurology Products, Dr. Russell G. Katz, and the drug was approved despite the FDA’s primary function of protecting citizens from harm caused by needlessly dangerous drugs — in this case, a drug barely more effective but significantly more dangerous than the lower doses of Aricept.

In May 2011, Public Citizen petitioned the FDA to ban Aricept 23. Public Citizen subsequently sued the FDA in September 2012, after the agency failed to respond to our petition. Today, the FDA decided that it had not made a mistake in approving the drug and rejected our petition to ban it. 

Although Eisai/Pfizer did lose 96 percent of their market on the patent-expired lower doses by this year, they have managed to sell 672,000 prescriptions of Aricept 23, taking in $172 million in U.S. sales between the original marketing in the summer of 2010 and September of this year. It is inevitable that thousands of Alzheimer’s patients were needlessly harmed, some fatally, by the FDA’s dangerous and legally questionable approval of Aricept 23. More will be injured and killed because of the FDA’s reckless adherence to their original mistaken approval.

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.